Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 291

1.

68Ga-PMSA Uptake in the Lung: Metastatic Versus Primary Lung Tumor.

Usmani S, Sadeq A, Marafi F, Esmail A, Al Kandari F, Ahmed N.

Clin Nucl Med. 2020 Feb;45(2):e80-e82. doi: 10.1097/RLU.0000000000002870.

PMID:
31876815
2.

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD.

Lancet Oncol. 2019 Dec 16. pii: S1470-2045(19)30788-0. doi: 10.1016/S1470-2045(19)30788-0. [Epub ahead of print]

PMID:
31859245
3.

Quadruplets come of age for newly diagnosed multiple myeloma.

Bhutani M, Usmani SZ.

Lancet. 2020 Jan 11;395(10218):94-96. doi: 10.1016/S0140-6736(19)33063-6. Epub 2019 Dec 10. No abstract available.

PMID:
31836198
4.

Extramedullary multiple myeloma.

Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ.

Leukemia. 2020 Jan;34(1):1-20. doi: 10.1038/s41375-019-0660-0. Epub 2019 Nov 27. Review.

PMID:
31776467
5.

Letter to the editor concerning "Single-institution experience of performing bloodless transplant in Jehovah's Witness patients" by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44-9.).

Zhao JC, Arnall JR, Martin AL, Usmani S, Atrash S.

Hematol Oncol Stem Cell Ther. 2019 Oct 11. pii: S1658-3876(19)30077-9. doi: 10.1016/j.hemonc.2019.08.007. [Epub ahead of print] No abstract available.

6.

Evaluation of the Potential Acetylcholinesterase Inhibitor-Induced Rhinorrhea Prescribing Cascade.

Vouri SM, Possinger MC, Usmani S, Solberg LM, Manini T.

J Am Geriatr Soc. 2019 Oct 18. doi: 10.1111/jgs.16224. [Epub ahead of print] No abstract available.

PMID:
31625144
7.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J; KEYNOTE-185 Investigators.

Lancet Haematol. 2019 Sep;6(9):e448-e458. doi: 10.1016/S2352-3026(19)30109-7. Epub 2019 Jul 18.

PMID:
31327689
8.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators.

Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18.

PMID:
31327687
9.

Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.

Shah J, Usmani S, Stadtmauer EA, Rifkin RM, Berenson JR, Berdeja JG, Lyons RM, Klippel Z, Chang YL, Niesvizky R.

Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):570-578.e1. doi: 10.1016/j.clml.2019.05.017. Epub 2019 May 29.

PMID:
31326409
10.

Normal Variant 18F-Sodium Fluoride Uptake in the Falx Cerebri Ossification.

Usmani S, Marafi F, Al Kandari F, Ahmed N.

Clin Nucl Med. 2019 Oct;44(10):804-805. doi: 10.1097/RLU.0000000000002741.

PMID:
31306210
11.

A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant.

Zhao JC, Arnall JR, Martin AL, Atrash S, Bhutani M, Voorhees P, Avalos B, Copelan E, Ghosh N, Hamadani M, Usmani S, Ford P.

Biol Blood Marrow Transplant. 2019 Oct;25(10):e305-e309. doi: 10.1016/j.bbmt.2019.07.003. Epub 2019 Jul 8. Review.

PMID:
31295572
12.

Adductor Insertion Avulsion Syndrome with Stress Fracture in Morbidly Obese Patient Diagnosed on 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography.

Usmani S, Marafi F, Al Kandari F, Ahmed N.

Indian J Nucl Med. 2019 Jul-Sep;34(3):256-257. doi: 10.4103/ijnm.IJNM_77_19.

13.

Tc-99m HDP Single Photon Emission Computed Tomography/Computed Tomography in Stress Fracture of Base of Metatarsal Bone.

Usmani S, Al-Ramadhan F, Marafi F, Rasheed R, Al Kandari F.

Indian J Nucl Med. 2019 Jul-Sep;34(3):251-253. doi: 10.4103/ijnm.IJNM_68_19.

14.

Molecular imaging of bone metastases using bone targeted tracers.

Vaz S, Usmani S, Gnanasegaran G, Van den Wyngaert T.

Q J Nucl Med Mol Imaging. 2019 Jun;63(2):112-128. doi: 10.23736/S1824-4785.19.03198-4. Epub 2019 Jul 8.

PMID:
31286752
15.

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma.

Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J.

Blood. 2019 Aug 22;134(8):668-677. doi: 10.1182/blood.2019000667. Epub 2019 Jul 3.

16.

PRRDB 2.0: a comprehensive database of pattern-recognition receptors and their ligands.

Kaur D, Patiyal S, Sharma N, Usmani SS, Raghava GPS.

Database (Oxford). 2019 Jan 1;2019. pii: baz076. doi: 10.1093/database/baz076.

17.

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies.

Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schecter JM, Qin X, O' Rourke L, Dimopoulos MA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217448. doi: 10.3324/haematol.2019.217448. [Epub ahead of print]

18.

Support of acute lymphoblastic leukemia cells by nonmalignant bone marrow stromal cells.

Usmani S, Sivagnanalingam U, Tkachenko O, Nunez L, Shand JC, Mullen CA.

Oncol Lett. 2019 Jun;17(6):5039-5049. doi: 10.3892/ol.2019.10188. Epub 2019 Mar 22.

19.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
20.

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators.

N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249.

PMID:
31141632
21.

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Paul B, Lipe B, Ocio EM, Usmani SZ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e176-e186. doi: 10.1200/EDBK_238527. Epub 2019 May 17.

22.

Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy.

Di Pilato M, Kim EY, Cadilha BL, Prüßmann JN, Nasrallah MN, Seruggia D, Usmani SM, Misale S, Zappulli V, Carrizosa E, Mani V, Ligorio M, Warner RD, Medoff BD, Marangoni F, Villani AC, Mempel TR.

Nature. 2019 Jun;570(7759):112-116. doi: 10.1038/s41586-019-1215-2. Epub 2019 May 15.

23.

Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review.

Usmani S, Orevi M, Stefanelli A, Zaniboni A, Gofrit ON, Bnà C, Illuminati S, Lojacono G, Noventa S, Savelli G.

Crit Rev Oncol Hematol. 2019 Jun;138:29-37. doi: 10.1016/j.critrevonc.2019.03.005. Epub 2019 Mar 30. Review.

PMID:
31092382
24.

Relative Risk of Adverse Events and Treatment Discontinuations Between Older and Non-Older Adults Treated with Antimuscarinics for Overactive Bladder: A Systematic Review and Meta-Analysis.

Usmani SA, Reckenberg K, Johnson O, Stranges PM, Teshome BF, Kebodeaux CD, Vouri SM.

Drugs Aging. 2019 Jul;36(7):639-645. doi: 10.1007/s40266-019-00674-9.

PMID:
31054113
25.

Immune Checkpoint Inhibitors (Nivolumab)-Induced Enterocolitis Demonstrated on 18Fluorine-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography.

Usmani S, Rasheed R, Marafi F, Al Kandari F.

Indian J Nucl Med. 2019 Apr-Jun;34(2):173-175. doi: 10.4103/ijnm.IJNM_141_18.

26.

Optimization of Radiation Exposure in 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography in Bone Imaging: Quo Vadis.

Rasheed R, Usmani S, Raza Naqvi SA, Alkandari F, Marafi FA, Rasheed S.

Indian J Nucl Med. 2019 Apr-Jun;34(2):157-159. doi: 10.4103/ijnm.IJNM_143_18. No abstract available.

27.

HumCFS: a database of fragile sites in human chromosomes.

Kumar R, Nagpal G, Kumar V, Usmani SS, Agrawal P, Raghava GPS.

BMC Genomics. 2019 Apr 18;19(Suppl 9):985. doi: 10.1186/s12864-018-5330-5.

28.

68Ga-Prostate-Specific Membrane Antigen PET/CT in Cholangiocarcinoma: A Potential Biomarker for Targeted Radioligand Therapy?

Marafi F, Usmani S, Esmail A.

Clin Nucl Med. 2019 Jul;44(7):e439-e441. doi: 10.1097/RLU.0000000000002563.

PMID:
30985434
29.

225Ac Prostate-Specific Membrane Antigen Posttherapy α Imaging: Comparing 2 and 3 Photopeaks.

Usmani S, Rasheed R, Al Kandari F, Marafi F, Naqvi SAR.

Clin Nucl Med. 2019 May;44(5):401-403. doi: 10.1097/RLU.0000000000002525.

PMID:
30932973
30.

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K.

Blood. 2019 Jul 11;134(2):123-133. doi: 10.1182/blood-2019-02-895193. Epub 2019 Mar 12.

31.

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ.

Leukemia. 2019 Sep;33(9):2266-2275. doi: 10.1038/s41375-019-0435-7. Epub 2019 Mar 11.

32.

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.

Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ.

Leuk Lymphoma. 2019 Sep;60(9):2295-2298. doi: 10.1080/10428194.2019.1576871. Epub 2019 Mar 8. No abstract available.

PMID:
30848971
33.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.

Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V.

Future Oncol. 2019 May;15(13):1411-1428. doi: 10.2217/fon-2019-0013. Epub 2019 Feb 28.

34.

ImmunoSPdb: an archive of immunosuppressive peptides.

Usmani SS, Agrawal P, Sehgal M, Patel PK, Raghava GPS.

Database (Oxford). 2019 Jan 1;2019. doi: 10.1093/database/baz012.

35.

Alpha Therapy with 225Actinium Labeled Prostate Specific Membrane Antigen: Reporting New Photopeak of 78 Kilo-electron Volts for Better Image Statistics.

Rasheed R, Usmani S, Naqvi SAR, Alkandari F, Marafi F.

Indian J Nucl Med. 2019 Jan-Mar;34(1):76-77. doi: 10.4103/ijnm.IJNM_115_18. No abstract available.

36.

Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States.

Li S, Natwick T, Liu J, Morrison VA, Vidito S, Werther W, Yusuf AA, Usmani SZ.

J Geriatr Oncol. 2019 May;10(3):490-496. doi: 10.1016/j.jgo.2019.01.007. Epub 2019 Jan 30.

PMID:
30709612
37.

Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.

Kumar A, Drusbosky LM, Meacham A, Turcotte M, Bhargav P, Vasista S, Usmani S, Pampana A, Basu K, Tyagi A, Lala D, Rajagopalan S, Birajdar SC, Alam A, Ghosh Roy K, Abbasi T, Vali S, Sengar M, Chinnaswamy G, Shah BD, Cogle CR.

Leuk Res. 2019 Mar;78:3-11. doi: 10.1016/j.leukres.2019.01.003. Epub 2019 Jan 7.

38.

HIV-1 Balances the Fitness Costs and Benefits of Disrupting the Host Cell Actin Cytoskeleton Early after Mucosal Transmission.

Usmani SM, Murooka TT, Deruaz M, Koh WH, Sharaf RR, Di Pilato M, Power KA, Lopez P, Hnatiuk R, Vrbanac VD, Tager AM, Allen TM, Luster AD, Mempel TR.

Cell Host Microbe. 2019 Jan 9;25(1):73-86.e5. doi: 10.1016/j.chom.2018.12.008.

39.

Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation.

Copelan OR, Sanikommu SR, Trivedi JS, Butler C, Ai J, Ragon BK, Jacobs R, Knight TG, Usmani SZ, Grunwald MR, Ghosh N, Symanowski JT, Shahid Z, Clark PE, He J.

Biol Blood Marrow Transplant. 2019 Apr;25(4):785-790. doi: 10.1016/j.bbmt.2018.12.142. Epub 2018 Dec 20.

PMID:
30579967
40.

Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.

Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P.

Biol Blood Marrow Transplant. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21.

PMID:
30579965
41.

High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.

Adams HC 3rd, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T.

Cytometry A. 2019 Mar;95(3):279-289. doi: 10.1002/cyto.a.23693. Epub 2018 Dec 11.

42.

Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.

Hussain MJ, Robinson MM, Hamadeh I, Arnall J, Bhutani M, Atrash S, Friend R, Pineda-Roman M, Symanowski JT, Usmani SZ, Voorhees PM.

Br J Haematol. 2019 Jul;186(1):140-144. doi: 10.1111/bjh.15716. Epub 2018 Dec 11. No abstract available.

PMID:
30536372
43.

Treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Usmani SZ, Seifter E.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):97-102. doi: 10.1182/asheducation-2018.1.97. Review. No abstract available.

44.

Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.

Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, Druhan LJ, Guo F, Rigby K, Turner M, Slaughter D, Friend R, Atrash S, Symanowski JT, Avalos BR, Copelan EA, Voorhees PM, Usmani SZ.

Biol Blood Marrow Transplant. 2019 Mar;25(3):459-465. doi: 10.1016/j.bbmt.2018.11.015. Epub 2018 Nov 24.

PMID:
30481597
45.

Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.

Arnall JR, Usmani SZ, Adamu H, Mishkin J, Bhutani M.

J Oncol Pharm Pract. 2019 Jun;25(4):1021-1025. doi: 10.1177/1078155218815305. Epub 2018 Nov 26.

PMID:
30477388
46.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

47.

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.

Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M.

Blood Cancer J. 2018 Nov 8;8(11):107. doi: 10.1038/s41408-018-0144-x. No abstract available.

48.

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK.

Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5.

49.

A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria.

Nagpal G, Usmani SS, Raghava GPS.

Front Immunol. 2018 Oct 2;9:2280. doi: 10.3389/fimmu.2018.02280. eCollection 2018.

50.

The clinical significance of incidental soft tissue uptake on whole body 18F-sodium fluoride bone PET-CT.

Usmani S, Gnanasegaran G, Marafi F, Esmail A, Ahmed N, Van den Wyngaert T.

Clin Radiol. 2019 Feb;74(2):95-110. doi: 10.1016/j.crad.2018.09.007. Epub 2018 Oct 17. Review.

PMID:
30340750

Supplemental Content

Loading ...
Support Center